

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
September 22-23, 2022

**MEETING ROSTER**

---

**DESIGNATED FEDERAL OFFICER (Non-Voting)**

**She-Chia Chen, PharmD**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Jorge A. Garcia, MD, FACP**

*(Chairperson)*

Chief, Division of Solid Tumor Oncology  
George & Edith Richman Distinguished Scientist Chair  
Professor of Medicine and Urology  
GU Medical Oncology Program  
University Hospitals Seidman Cancer Center  
Case Comprehensive Cancer Center  
Case Western Reserve University  
Cleveland, Ohio

**Ranjana H. Advani, MD**

*(September 23 only)*

Saul A. Rosenberg Professor of Lymphoma  
Division of Oncology  
Stanford University School of Medicine  
Stanford, California

**Pamela L. Kunz, MD**

*(September 22 only)*

Associate Professor of Medicine (Oncology)  
Division Chief, GI Oncology  
Vice Chief  
Diversity Equity and Inclusion, Medical Oncology  
Yale School of Medicine and Yale Cancer Center  
New Haven, Connecticut

**Christopher H. Lieu, MD**

Associate Professor of Medicine  
Associate Director for Clinical Research  
co-Director, Gastrointestinal Medical Oncology  
University of Colorado Cancer Center  
Aurora, Colorado

**Ravi A. Madan, MD**

Senior Clinician, Genitourinary Malignancies Branch  
Head, Prostate Cancer Clinical Research Section  
Program Director, Physician-Scientist Early  
Investigator Program  
Center for Cancer Research  
National Cancer Institute, National Institutes of Health  
Bethesda, Maryland

**David E. Mitchell**

*(Consumer Representative)*

Founder, Patients for Affordable Drugs  
Bethesda, Maryland

**Jorge J. Nieva, MD**

*(September 22 PM session and September 23 only)*

Associate Professor of Clinical Medicine  
Section Head, Solid Tumors  
University of Southern California (USC) Norris  
Comprehensive Cancer Center  
Keck School of Medicine of USC  
Los Angeles, California

**Ashley Rosko, MD**

*(September 22 AM session only)*

Associate Professor  
Division of Hematology  
Medical Director Oncogeriatric  
The Ohio State University Comprehensive Cancer  
Center  
Columbus, Ohio

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
September 22-23, 2022

**MEETING ROSTER (cont.)**

---

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting) (cont.)**

**Anthony D. Sung, MD**

*(September 22 only)*

Associate Professor of Medicine  
Duke University School of Medicine  
Duke Adult Blood and Marrow Transplant Clinic  
Durham, North Carolina

**ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)**

**Albert L. Kraus, PhD**

*(Acting Industry Representative)*

Global Regulatory Portfolio Lead – Oncology  
Pfizer, Inc.  
Guilford, Connecticut

**TEMPORARY MEMBERS (Voting)**

**Andy I. Chen MD, PhD**

*(September 22 PM session and September 23 only)*

Associate Professor, Center for Hematologic  
Malignancies  
Oregon Health & Science University  
Portland, Oregon

**Stephanie Y. Crawford, PhD, MPH**

*(September 22 PM session and September 23 only)*

Executive Associate Dean for Faculty Affairs &  
Strategic Initiatives  
Professor, Department of Pharmacy Systems,  
Outcomes and Policy  
University of Illinois Chicago (UIC) College of  
Pharmacy  
Chicago, Illinois

**John DeFlice, MD**

*(Patient Representative for September 22 PM  
session only)*

Albuquerque, New Mexico

**Boris Freidlin, PhD, MS**

*(September 22 PM session and September 23 only)*

Branch Chief, Biostatistics Branch  
Division of Cancer Treatment & Diagnosis  
National Cancer Institute  
Bethesda, Maryland

**Balazs Halmos, MD**

*(September 22 AM session only)*

Associate Director for Clinical Science  
Montefiore Einstein Cancer Center  
Professor of Medicine  
Albert Einstein College of Medicine  
Bronx, New York

**David Harrington, MA, PhD**

Professor of Biostatistics (Emeritus)  
Harvard T.H. Chan School of Public Health and  
Dana-Farber Cancer Institute  
Boston, Massachusetts

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
September 22-23, 2022

**MEETING ROSTER (cont.)**

---

**TEMPORARY MEMBERS (Voting) (cont.)**

**Mary Kwok, MD**

*(September 22 PM session only)*

Clinical Associate Professor,  
Division of Hematology  
University of Washington, Seattle, WA  
Fred Hutchinson Cancer Center  
Seattle, Washington

**Michele Nadeem-Baker, MS**

*(Patient Representative for September 23 only)*

Charlestown, Massachusetts

**Grzegorz (Greg) S. Nowakowski MD**

*(September 22 PM session only)*

Professor of Medicine and Oncology  
Deputy Director for Clinical Research  
Mayo Clinic Comprehensive Cancer Center  
Rochester, Minnesota

**James (Jim) G. Pantelas**

*(Patient Representative for September 22 AM session only)*

Howell, Michigan

**Mikael A. Sekeres, MD, MS**

*(September 22 PM session and September 23 only)*

Professor of Medicine  
Sylvester Cancer Center  
University of Miami  
Miami, Florida

**Katherine Scilla, MD, FACP**

*(September 22 AM session only)*

Assistant Professor of Medicine  
University of Maryland School of Medicine  
Baltimore, Maryland

**Anish Thomas, MD**

*(September 22 AM session only)*

Investigator, Center for Cancer Research  
Developmental Therapeutics Branch  
National Cancer Institute  
Bethesda, Maryland

**Scott A. Waldman, MD, PhD, FCP, FAHA, FNAL, FASPET**

*(September 22 only)*

Chair, Department of Pharmacology, Physiology, &  
Cancer Biology  
Samuel M.V. Hamilton Professor of Medicine  
Jefferson (Philadelphia University + Thomas  
Jefferson University)  
Philadelphia, Pennsylvania

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
September 22-23, 2022

**MEETING ROSTER (cont.)**

---

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

Director, Oncology Center of Excellence (OCE)  
Director (Acting)  
Office of Oncologic Diseases (OOD)  
Office of New Drugs (OND), CDER, FDA

**Julia Beaver, MD**

*(September 22 AM session only)*  
Chief of Medical Oncology, OCE  
Deputy Director (Acting), OOD  
OND, CDER, FDA

**Nicole Gormley, MD**

*(September 22 PM session and September 23 only)*  
Director  
Division of Hematologic Malignancies II (DHM II)  
OOD, OND, CDER, FDA

**Bindu Kanapuru, MD**

*(September 22 PM session only)*  
Clinical Team Leader  
DHM II, OOD, OND, CDER, FDA

**Justin Malinou, MD**

*(September 22 AM session only)*  
Clinical Reviewer  
DO2, OOD, OND, CDER, FDA

**Alexandria Schwarsin, MD**

*(September 22 PM session only)*  
Clinical Reviewer  
DHM II, OOD, OND, CDER, FDA

**Marc R. Theoret, MD**

*(September 22 PM session and September 23 only)*  
Deputy Center Director, OCE  
Supervisory Associate Director (Acting)  
OOD, OND, CDER, FDA

**Harpreet Singh, MD**

*(September 22 AM session only)*  
Director  
Division of Oncology 2 (DO2)  
OOD, OND, CDER, FDA

**Nicole Drezner, MD**

*(September 22 AM session only)*  
Clinical Team Lead  
DO2, OOD, OND, CDER, FDA

**Nicholas Richardson, DO, MPH**

*(September 23 only)*  
Clinical Team Leader  
DHM II, OOD, OND, CDER, FDA

**Jeanne Fourie Zirkelbach, PhD**

*(September 22 AM session only)*  
Team Lead, Clinical Pharmacology  
Division of Cancer Pharmacology 2  
Office of Clinical Pharmacology  
Office of Translational Sciences, CDER, FDA

**Deepti Telaraja, MD**

*(September 23 only)*  
Clinical Reviewer  
DHM II, OOD, OND, CDER, FDA